share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144：擬議出售證券
SEC announcement ·  03/23 04:03
牛牛AI助理已提取核心訊息
CRISPR Therapeutics officer Phuong Khanh Morrow is set to sell 50,767 shares of the company's common stock on 03/22/2024, as per the latest filings. The shares, valued at approximately $3,699,269.45, were acquired on the same date through the exercise of stock options. The transaction involved a cash payment to the issuer for the securities. This sale comes without any reported transactions by Morrow in the past three months.
CRISPR Therapeutics officer Phuong Khanh Morrow is set to sell 50,767 shares of the company's common stock on 03/22/2024, as per the latest filings. The shares, valued at approximately $3,699,269.45, were acquired on the same date through the exercise of stock options. The transaction involved a cash payment to the issuer for the securities. This sale comes without any reported transactions by Morrow in the past three months.
根據最新文件，CRISPR Therapeutics高管Phuong Khanh Morrow定於2024年3月22日出售該公司50,767股普通股。這些股票的價值約爲3,699,269.45美元，是同日通過行使股票期權收購的。該交易涉及向發行人支付證券的現金。在過去的三個月中，Morrow沒有報告任何交易。
根據最新文件，CRISPR Therapeutics高管Phuong Khanh Morrow定於2024年3月22日出售該公司50,767股普通股。這些股票的價值約爲3,699,269.45美元，是同日通過行使股票期權收購的。該交易涉及向發行人支付證券的現金。在過去的三個月中，Morrow沒有報告任何交易。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。